These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577 [TBL] [Abstract][Full Text] [Related]
4. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Webster-Gandy JD; How C; Harrold K Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337 [TBL] [Abstract][Full Text] [Related]
5. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment]. Risum S; Langer SW Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412 [TBL] [Abstract][Full Text] [Related]
6. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia. Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651 [TBL] [Abstract][Full Text] [Related]
7. [Hand-foot syndrome (palmar-plantar erythrodysesthesia]. Salzberg M; Herrmann R Schweiz Med Wochenschr; 2000 Oct; 130(40):1413-6. PubMed ID: 11059033 [TBL] [Abstract][Full Text] [Related]
11. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Lipworth AD; Robert C; Zhu AX Oncology; 2009; 77(5):257-71. PubMed ID: 19923864 [TBL] [Abstract][Full Text] [Related]
12. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468 [TBL] [Abstract][Full Text] [Related]
13. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience. Rossi D; Catalano G Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894 [No Abstract] [Full Text] [Related]
14. Chemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and soles. Ziemer M; Goetze S; Kaatz M; Elsner P J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S44-6. PubMed ID: 18191705 [No Abstract] [Full Text] [Related]
15. Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event? Iurlo A; Fornier M; Caldiera S; Bertoni F; Foa P Acta Oncol; 1997; 36(6):653-4. PubMed ID: 9408159 [No Abstract] [Full Text] [Related]
16. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Fabian CJ; Molina R; Slavik M; Dahlberg S; Giri S; Stephens R Invest New Drugs; 1990 Feb; 8(1):57-63. PubMed ID: 2345070 [TBL] [Abstract][Full Text] [Related]
17. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E Oncology; 2006; 70(2):141-6. PubMed ID: 16645327 [TBL] [Abstract][Full Text] [Related]
18. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868 [TBL] [Abstract][Full Text] [Related]
19. Fluorouracil and palmar-plantar erythrodysesthesia. Curran CF; Luce JK Ann Intern Med; 1989 Nov; 111(10):858. PubMed ID: 2817635 [No Abstract] [Full Text] [Related]